NCT00232193 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Status COMPLETED Phase N/A
NCT00223457 Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis Status COMPLETED Phase N/A
NCT00223301 Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis Status COMPLETED Phase PHASE2/PHASE3
NCT00193505 Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma Status COMPLETED Phase PHASE2
NCT00193440 Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE2
NCT00186589 90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL Status COMPLETED Phase PHASE1
NCT00179478 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Status COMPLETED Phase PHASE4
NCT00177554 Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma Status COMPLETED Phase PHASE2
NCT00168766 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Status COMPLETED Phase PHASE4
NCT00168740 Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) Status COMPLETED Phase PHASE3
NCT00168727 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE4
NCT00135733 A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus Status TERMINATED Phase PHASE2
NCT00119730 Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma Status COMPLETED Phase PHASE2
NCT00117156 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE2